- Home
- OPHC vs IMA Comparison
OPHC vs IMA Comparison
Compare OPHC & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | IMA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 65.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OPHC | IMA |
|---|---|---|
| Price | $5.44 | $6.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 32.4K | ★ 32.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,115.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $5.70 |
| 52 Week High | $5.59 | $17.50 |
Technical Indicators
Market Signals| Indicator | OPHC | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 68.14 | 39.24 |
| Support Level | $4.00 | $5.97 |
| Resistance Level | $5.59 | $7.17 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 65.63 | 10.26 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.